Key result
Cardiac involvement in Erdheim-Chester disease was present in 48% of patients but was not associated with lower survival (adjusted HR 1.4; 95% CI 0.8-2.5; P=0.2).
Why the study?
Does cardiac involvement affect all-cause mortality in patients with Erdheim-Chester disease?
Cohort (n=200)
No
Does cardiac involvement affect all-cause mortality in patients with Erdheim-Chester disease?
Cardiac involvement is common in Erdheim-Chester disease and is associated with complications but does not significantly impact overall survival.
AIMS: Cardiac involvement of Erdheim-Chester disease (ECD), a rare L group histiocytosis, has been reported to be associated with poor outcomes, but systematic studies are lacking. The present study aimed to investigate the prevalence, clinical features, imaging features, and prognosis of cardiac involvement in ECD in a large series. METHODS AND RESULTS: All patients with ECD who underwent cardiac magnetic resonance (CMR) imaging between 2003 and 2019 at a French tertiary center were retrospectively included. Primary outcome was all-cause mortality. Secondary outcomes were pericarditis, cardiac tamponade, conduction disorders, device implantation and coronary artery disease (CAD). A total of 200 patients were included [63 (54-71) years, 30% female, 58% BRAFV600E mutated]. Median follow-up was 5.5 years (3.3-9 years). On CMR, right atrioventricular sulcus infiltration was observed in 37% of patients, and pericardial effusion was seen in 24% of patients. In total, 8 patients (4%) had pericarditis (7 acute, 1 constrictive), 10 patients (5%) had cardiac tamponade, 5 patients (2.5%) had ECD-related high-degree conduction disorders, and 45 patients (23%) had CAD. Overall, cardiac involvement was present in 96 patients (48%) and was associated with BRAFV600E mutation [Odds ratio (OR) = 7.4, 95% confidence interval (CI) (3.5-16.8), P < 0.001] and ECD-related clinical events [OR = 5, 95%CI (1.5-21.2), P = 0.004] but not with lower survival in multivariate analysis [adjusted hazard ratio (HR) = 1.4, 95% CI (0.8-2.5), P = 0.2]. CONCLUSION: Cardiac involvement is present in nearly half of ECD patients and is associated with BRAFV600E mutation and complications (pericarditis, cardiac tamponade, and conduction disorders) but not with lower survival.
No takes yet. Share an insight, caveat, or question.
Azoulay et al. (2022) conducted a cohort in Erdheim-Chester disease (n=200). Cardiac involvement vs. No cardiac involvement was evaluated on All-cause mortality (HR 1.4, 95% CI 0.8-2.5, p=0.2). Cardiac involvement in Erdheim-Chester disease was present in 48% of patients but was not associated with lower survival (adjusted HR 1.4; 95% CI 0.8-2.5; P=0.2).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: